Related Experiment Video

Updated: May 3, 2026

Laboratory Administration of Transcutaneous Auricular Vagus Nerve Stimulation taVNS: Technique, Targeting, and Considerations
06:31

Laboratory Administration of Transcutaneous Auricular Vagus Nerve Stimulation taVNS: Technique, Targeting, and Considerations

Published on: January 7, 2019

43.0K

An alternative therapy for drug-resistant epilepsy: transcutaneous auricular vagus nerve stimulation

Peijing Rong1, Aihua Liu2, Jianguo Zhang3

  • 1Function Laboratory, Institute of Acu-Mox, China Academy of Chinese Medical Sciences, Beijing 100700, China.

Chinese Medical Journal
|January 21, 2014
PubMed
Abstract

More Related Videos

Transauricular Vagus Nerve Stimulation and Electroencephalographic Assessment in Disorders of Consciousness04:04

Transauricular Vagus Nerve Stimulation and Electroencephalographic Assessment in Disorders of Consciousness

Published on: July 11, 2025

2.2K
Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression04:29

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression

Published on: January 7, 2019

31.9K

Related Concept Videos

Electroconvulsive Therapy01:30

Electroconvulsive Therapy

Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
2.6K
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
1.2K